revenue for Q4 2023, with the Company reporting $148.1M (US$97.1M1) of total product revenue, primarily generated from sales of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the United States, an increase of 11% on the prior quarter (Q3 2023) total revenue of $133.6M (US$87.2M2).
Growth in Illuccix hasnt petered out at all.
its growing
and 19% increase in dose volume.
gawd
cant complain there can we ....(someone will )
well done CB
i was praying for the magic $150. but hoping not to see and shortfalls. and you've delivered
noice
200% growth in 2023 - hello !?
and its not 200% from smalls ... its half a Billion dollars and growing
Ann: JP Morgan Healthcare Conference Presentation, page-3
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.48 |
Change
0.030(0.15%) |
Mkt cap ! $6.854B | |||
| Open | High | Low | Value | Volume |
| $20.35 | $20.83 | $20.30 | $10.68M | 520.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1586 | $20.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.58 | 898 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| TLX (ASX) Chart |